Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Common Stock | 25.8M | $63.5M | $2.46 | Nov 26, 2024 | Direct |
Liquidia Corp | Director | Common Stock | 3.13M | $27.9M | $8.90 | Sep 12, 2024 | Direct |
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Common Stock | 5.98M | $14.7M | $2.46 | Nov 22, 2024 | Indirect |
Taysha Gene Therapies, Inc. | 10%+ Owner | Common Stock | 4.84M | $10.9M | $2.25 | Jun 27, 2024 | Indirect |
Candel Therapeutics, Inc. | Director | Common Stock | 1.68M | $10.1M | $6.00 | Dec 16, 2024 | Direct |
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Common Stock | 3.32M | $8.18M | $2.46 | Nov 22, 2024 | By trust |
Candel Therapeutics, Inc. | Director | Common Stock | 1.3M | $7.82M | $6.00 | Dec 16, 2024 | By BKB Growth Investments, LLC |
Liquidia Corp | Director | Common Stock | 816K | $7.27M | $8.90 | Sep 12, 2024 | Indirect |
Candel Therapeutics, Inc. | Director | Common Stock | 1.14M | $6.85M | $6.00 | Dec 16, 2024 | By Paul B. Manning Revocable Trust |
Taysha Gene Therapies, Inc. | 10%+ Owner | Common Stock | 1.33M | $3M | $2.25 | Jun 27, 2024 | Direct |
Acumen Pharmaceuticals, Inc. | 10%+ Owner | Common Stock | 658K | $2.28M | $3.47 | Jul 6, 2021 | Indirect |
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Series A Warrants (right to buy) | 9.21M | Nov 22, 2024 | Direct | ||
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Series B Warrants (right to buy) | 9.21M | Nov 22, 2024 | Direct | ||
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Series A Warrants (right to buy) | 2.25M | Nov 22, 2024 | Indirect | ||
Verrica Pharmaceuticals Inc. | Director, 10%+ Owner | Series B Warrants (right to buy) | 2.25M | Nov 22, 2024 | Indirect | ||
Candel Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 14.2K | Jun 26, 2024 | Direct | ||
Acumen Pharmaceuticals, Inc. | 10%+ Owner | Series A-1 Preferred Stock | 0 | Jul 6, 2021 | Indirect | ||
Acumen Pharmaceuticals, Inc. | 10%+ Owner | Series B Preferred Stock | 0 | Jul 6, 2021 | Indirect |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
CADL | Candel Therapeutics, Inc. | Dec 16, 2024 | 2 | $7.5M | 4 | Dec 18, 2024 | Director |
VRCA | Verrica Pharmaceuticals Inc. | Nov 22, 2024 | 7 | $0 | 4 | Nov 26, 2024 | Director, 10%+ Owner |
VRCA | Verrica Pharmaceuticals Inc. | Sep 19, 2024 | 4 | $0 | 4 | Sep 23, 2024 | Director, 10%+ Owner |
LQDA | Liquidia Corp | Sep 12, 2024 | 1 | $3M | 4 | Sep 16, 2024 | Director |
TSHA | Taysha Gene Therapies, Inc. | Jun 27, 2024 | 1 | $3M | 4 | Jul 1, 2024 | 10%+ Owner |
CADL | Candel Therapeutics, Inc. | Jun 26, 2024 | 1 | $0 | 4 | Jun 27, 2024 | Director |
LQDA | Liquidia Corp | Jun 20, 2024 | 1 | $0 | 4 | Jun 24, 2024 | Director |
LQDA | Liquidia Corp | Dec 14, 2023 | 1 | $2M | 4 | Dec 18, 2023 | Director |
TSHA | Taysha Gene Therapies, Inc. | Nov 17, 2023 | 1 | $163K | 4 | Nov 20, 2023 | 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | Aug 16, 2023 | 1 | $14.8M | 4 | Aug 16, 2023 | 10%+ Owner |
VRCA | Verrica Pharmaceuticals Inc. | Jul 24, 2023 | 1 | $1M | 4 | Jul 24, 2023 | Director, 10%+ Owner |
CADL | Candel Therapeutics, Inc. | Jun 28, 2023 | 1 | $0 | 4 | Jun 29, 2023 | Director |
LQDA | Liquidia Corp | Jun 19, 2023 | 1 | $0 | 4 | Jun 21, 2023 | Director |
TSHA | Taysha Gene Therapies, Inc. | Oct 31, 2022 | 1 | $3M | 4 | Nov 2, 2022 | Director, 10%+ Owner |
CADL | Candel Therapeutics, Inc. | Oct 13, 2022 | 1 | $0 | 4 | Oct 17, 2022 | Director |
VRCA | Verrica Pharmaceuticals Inc. | Jul 5, 2022 | 1 | $10M | 4 | Jul 5, 2022 | Director, 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | Jun 17, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director, 10%+ Owner |
LQDA | Liquidia Corp | Jun 17, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director |
LQDA | Liquidia Corp | Apr 18, 2022 | 1 | $2M | 4 | Apr 19, 2022 | Director |
LQDA | Liquidia Corp | Mar 31, 2022 | 1 | $0 | 4 | Apr 20, 2022 | Director |
TSHA | Taysha Gene Therapies, Inc. | Feb 2, 2022 | 5 | $1.57M | 4 | Feb 4, 2022 | Director, 10%+ Owner |
LQDA | Liquidia Corp | Dec 31, 2021 | 0 | $0 | 5/A | May 4, 2022 | Director, 10%+ Owner |
VRCA | Verrica Pharmaceuticals Inc. | Dec 31, 2021 | 2 | $0 | 5 | Feb 14, 2022 | Director, 10%+ Owner |
CADL | Candel Therapeutics, Inc. | Dec 31, 2021 | 1 | $0 | 5 | Feb 14, 2022 | Director, 10%+ Owner |
VRCA | Verrica Pharmaceuticals Inc. | Dec 2, 2021 | 2 | $468K | 4 | Dec 6, 2021 | Director, 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | Nov 24, 2021 | 1 | $29K | 4 | Nov 29, 2021 | Director, 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | Nov 23, 2021 | 1 | $251K | 4 | Nov 24, 2021 | Director, 10%+ Owner |
LQDA | Liquidia Corp | Aug 20, 2021 | 1 | $0 | 4 | Sep 1, 2021 | Director |
CADL | Candel Therapeutics, Inc. | Jul 29, 2021 | 5 | $13M | 4/A | Aug 4, 2021 | Director, 10%+ Owner |
CADL | Candel Therapeutics, Inc. | Jul 27, 2021 | 2 | $411K | 4 | Jul 29, 2021 | Director |
CADL | Candel Therapeutics, Inc. | Jul 26, 2021 | 0 | $0 | 3 | Jul 26, 2021 | Director |
ABOS | Acumen Pharmaceuticals, Inc. | Jul 6, 2021 | 6 | $5M | 4 | Jul 8, 2021 | 10%+ Owner |
ABOS | Acumen Pharmaceuticals, Inc. | Jun 30, 2021 | 0 | $0 | 3 | Jun 30, 2021 | 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | Jun 17, 2021 | 1 | $0 | 4 | Jun 21, 2021 | Director, 10%+ Owner |
TSHA | Taysha Gene Therapies, Inc. | May 14, 2021 | 1 | $252K | 4 | May 17, 2021 | Director, 10%+ Owner |